120
Views
10
CrossRef citations to date
0
Altmetric
Research Article

A Normative Study of the Components of Niprisan—an Herbal Medicine for Sickle Cell Anemia

, PhD, , BSc (Hon), , HND., , HND., , ND., , HND., , HND. & , PhD. show all
Pages 21-30 | Received 23 Apr 2009, Accepted 05 Nov 2009, Published online: 03 Mar 2010

REFERENCES

  • Ankrah EK, Dovlo FE. The properties of trona and its effect on the cooking time of cowpeas. J Sci Food Agric. 2006;29(11):950–952.
  • Awodogan A, Wambebe C, Gamaniel K, Okogun J, Orisadipe A, Akah P. Acute and short-term toxicity of NIPRISAN® in Rats I: biochemical study. J Pharmaceut Res Dev. 1996;2:39–45.
  • Awosiyan K. Nigeria has highest sickle cell patients. Nigeria Tribune, 14th December, 2006. Lagos, Nigeria, p.1.
  • Bandaranayake WM. Quality control, screening, toxicity, and regulation of herbal drugs. In: Iqbal Ahmad, Farrukh Aqil, and Mohammad Owais ( Eds.), Modern Phytomedicine – Turning Medicinal Plants into Drugs, pp. 25–57. Weinheim, Germany: WILEY-VCH Verlag GmbH & Co. KGaA, 2006.
  • British Pharmacopoeia. British Pharmacopoeia, 2004. Volume IV. The Stationery Office Limited, London. Appendix II D, Atomic spectrophotometry: emission and absorption, pp. A143-145. Determination of pH, pp. A143-145; Appendix VL, Determination of pH Values, pp. A199-A200, 2004.
  • Cordeiro NJV, Oniyangi O. Phytomedicines [medicines derived from plants] for sickle cell disease. The Cochrane Database of Systematic Review 2006 Issue 3. The Cochrane Library (ISSN 1464-780X), 2006.
  • Gamaniel K, Amos S, Akah P, Samuel B, Olusola A, Abayomi O, Pharmacological profile of NIPRD 94/002/1-0: a novel herbal antisickling agent. J Pharmaceut Res Dev. 1998;3(2):89–94.
  • Iyamu EW, Turner EA, Asakawa T. Niprisan [Nix-0699] improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Brit J Haematol. 2003;122(6):1001–1008.
  • Pandey RC. Xechem's Sickle Cell Drug, NIPRISAN -HEMOXIN- Granted Orphan Drug Status by the FDA NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Sept. 2, 2003–Xechem International, Inc. (OTC BB: XKEM). Xechem's Sickle Cell Drug, NIPRISAN -HEMOXIN- Granted Orphan Drug Status by… (cited November, 20th 2009), 2003.
  • Steinberg MH. Management of sickle cell disease. New Engl J Med. 1999;340(13):1021–1030. http://content.nejm.org/cgi/content/full/3401/1021
  • The mineral trona – Accessed from: http://minerals.galleries.com/minerals/carbonate/class.htm (cited November, 20th 2009)
  • Waknine Y. Orphan Drug Niprisan (Nicosan/Hemoxin) for Sickle Cell Disease in EU. International Approvals. October, 2005 http://www.medscape.com/px/viewindex/more?Bucket=columns&sectionId=2557 (cited November, 20th 2009), 2005.
  • Wambebe CO, Elijah AB, Badru BO, Khamofu H, Momoh JA, Ekpeyong M, Efficacy of Niprisan in the prophylactic management of patients with sickle cell disease. Curr Ther Res. 2001;62(1):26–34. ISSN 0011-393X CODEN CTCEA9. Efficacy of niprisan in the prophylactic management of patients with sickle cell disease
  • Wambebe C, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku SO, Double-blind, placebo-controlled, randomized cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine. 2001 Jul;8(4):252–261. doi:10.1078/0944-7113-00040
  • WHO. Chemistry-Manufacturing-Control (CMC) considerations for herbal products. Information needed to support Clinical Trials of herbal products. 2005. pp. 1–16.
  • WHO. Sickle-cell disease and other haemoglobin disorders. August 2006, WHO, Geneva, Fact sheet N°308, 2006.
  • WHO. 1998. Quality control methods for medicinal plant materials, pp. 1–115. Geneva: WHO, 1998.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.